Julia Rotow News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint

/PRNewswire/ Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically.

Dana farber cancer instituteUnited statesJacobio pharmaYuankai shiJulia rotowPrnewswire jacobio pharmaCancer hospital chinese academy of medical sciencesCancer hospital chinese academyMedical sciencesInduced allosteric drug discovery platform

Jacobio s KRAS data tee up safety-focused lung cancer pitch

Jacobio s KRAS data tee up safety-focused lung cancer pitch
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Amgen lumakrasInnovent biologicsJacobio pharmaDana farber cancer institute julia rotowBristol myers squibbFarber cancer instituteJulia rotow

Glecirasib Shows Promising Efficacy in KRAS-Mutated NSCLC

Trend towards better response rate, PFS compared with approved KRAS inhibitors

United statesDana farber cancer instituteJulia rotowYuankai shiMike bassettEastern cooperative oncology groupAmerican society of clinical oncologyChinese academy of medical sciencesUnion medical collegeChinese academyMedical sciencesPeking union medical collegeAmerican societyClinical oncology

Glecirasib Generates Durable Responses in Pretreated Advanced KRAS G12C+ NSCLC

Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.

United statesDana farber cancer instituteJulia rotowYuankai shiUnion medical collegeNational cancer center hospitalThoracic oncology at dana farber cancer instituteHarvard medical schoolChinese academy of medical sciencesLowe centerNational cancerCancer hospitalChinese academyMedical sciencesPeking union medical collegeThoracic oncology

Emerging Data Highlight Potential for Frontline Combinations in EGFR+ NSCLC

Ongoing research evaluating combination therapies for the frontline treatment of patients with EGFR-mutated non–small cell lung cancer could help improve survival outcomes for this patient population.

South koreaNew yorkUnited statesJulia rotowDana farber cancer instituteEuropean society for medical oncology congressAnnual new york lung cancersAnnual new york lung cancers symposiumEuropean societyMedical oncology congressLung cancerNew york lung cancer symposium